Sunday, October 11 – Recent research shows that structured support may help with weight maintenance after stopping GLP-1s. licensed miniseries · E+/Getty

Most people regain a significant portion of the

Satureday, October 10 – Eli Lilly and Co. has sued an Arizona weight loss clinic and three online sellers, alleging they are illegally selling products containing the pharmaceutical giant’s investigational

Satureday, October 10 – HHS is cranking up its efforts to accelerate drug development; more reports are emerging about off target effects of obesity drugs.

Friday, October 9 – In a new study, GLP-1 users reported nail detachment more than four times as often as nonusers. Waishaw/Getty Images

GLP-1 drugs like Ozempic have been linked

Thursday, October 8 – A new analysis found that the diabetes medication orforglipron (Foundayo), an oral GLP-1, helped women lose weight regardless of their menopausal status. Healthline/Photo by Eli Lilly

Thursday, October 8 – Recent research shows people who switch to the Wegovy pill from a GLP-1 injection can lose additional weight. PixelsEffect · E+/Getty

People with overweight or obesity

Thursday, October 8 – Boehringer reports cardiometabolic improvements in people with t2d

Thursday, October 8 – “She definitely wasn’t the same person after starting GLP-1s.”View Entire Post ›

Thursday, October 8 – Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference and other

Thursday, October 8 – (MedPage Today) — Isometric exercise training — such as squats and plank exercises — was best done three times a week for short-term blood pressure (BP)-lowering

Thursday, October 8 – (MedPage Today) — What menopause-related information can be tracked by wearable devices such as Apple watches? (New York Times)
GLP-1 medication prescribing surged from 2017

Tuesday, September 6 – Recent research suggests that increasing your Ozempic dose may offer greater heart protection than switching to Mounjaro. Eva Kongshavn · Moment/Getty

A real-world study found that

Tuesday, September 6 – Exposure to GLP-1 weight-loss and diabetes drugs around conception is not linked to a clearly detectable increase in adverse outcomes for mothers or babies, according to

Tuesday, October 6 – Despite the president’s comments, patients say these medications have been life-changing, and their effectiveness cannot be ignored.

Sunday, October 4 – Welcome back to another edition of Endpoints Weekly! It’s October 3rd, the day he asked me what day it was. “It’s October 3rd,” I told him.

Saturday, October 3 – In the United Kingdom, 2.9% of patients undergoing anesthesia reported receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a study published online Sept. 16 in

Saturday, October 3 – (MedPage Today) — The investigational triple agonist retatrutide substantially improved glycemic control and body weight in adults with obesity and type 2 diabetes, a phase III

Saturday, October 3 – Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine

Friday, October 2 – (MedPage Today) — Users of GLP-1 receptor agonists had as much as fourfold higher likelihood for nail disorders, particularly onycholysis (separation of the fingernails or toenails),

Friday, October 2 – More U.S. women are being prescribed GLP-1 medications after giving birth, particularly those diagnosed with diabetes, according to new research from the USC Schaeffer Center for

Friday, October 2 – (MedPage Today) — An investigational dual GIP/GLP-1 agonist achieved modest weight loss in adults with type 2 diabetes and obesity, the phase III SYNCHRONIZE-2 trial showed,

Friday, October 2 – (MedPage Today) — Starting a GLP-1 receptor agonist after giving birth is becoming more common, an analysis of claims data showed.
The percentage of women

Friday, October 2 – (MedPage Today) — In upstate New York, a nurse was choked with a stethoscope by a patient in the emergency room, according to police. (Syracuse.com)

Thursday, October 1 – “Intervening in childhood could save children from decades of irreversible damage,” a transplant surgeon writes of GLP-1 weight loss drugs.

Thursday, October 1 – The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept

Thursday, October 1 – New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from Sept. 28–Oct. 2 examined the

Thursday, October 1 – Nail detachment is more than four times as common among people taking GLP-1 receptor agonists as among comparable people with obesity or type 2 diabetes who

Thursday, October 1 – New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and in press

Thursday, October 1 – (MedPage Today) — Orforglipron (Foundayo) was able to claim cardiovascular safety based on the ACHIEVE-4 trial, though heart benefits remain unproven.
Among adults with type

Thursday, October 1 – Federal prosecutors have charged two people in an alleged scheme to bring fake versions of the type 2 diabetes drug Ozempic from China and sell them

Thursday, October 1 – (MedPage Today) — Use of GLP-1 receptor agonists around pregnancy did not appear to increase adverse maternal or perinatal outcomes, according to two studies.
In

Thursday, October 1 – New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in

Thursday, October 1 – Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor’s instructions. But a new study from the University of Georgia suggests patients

Thursday, October 1 – EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial

Thursday, October 1 – An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.

Thursday, October 1 – New research to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and

Thursday, October 1 – Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of

Thursday, October 1 – New trial data for the weight loss drug called retatrutide shows it helped people living with obesity and type 2 diabetes lose up to 50lbs or

Wednesday, September 30 – (MedPage Today) — GLP-1s and Stroke

Wednesday, September 30 – (MedPage Today) — The FDA designated Vitruvias Therapeutics’ recall of a lot of 30-mg levothyroxine-liothyronine tablets (Thyroid Tablets) as Class I, its most serious classification. (USA

Tuesday, September 29 – New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, found no link

Tuesday, September 29 – The number of people using GLP-1 treatments like Ozempic and Wegovy for weight loss or chronic conditions has increased rapidly, with more than 1 in 10

Tuesday, September 29 – Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to look and feel better

Tuesday, September 29 – Blockbuster GLP-1 drugs have transformed the lives of millions of people. Lately, they’re undergoing a makeover of their own.

Monday, September 28 – New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, makes a

Monday, September 28 – Experts share what you need to know about GLP-1-related hair loss as the side-effect gets more attention from researchers About 20 million people across the US,

Sunday, September 27 – New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show

Sunday, September 27 – Tirzepatide, sold as Mounjaro and Zepbound, activated calorie-burning brown fat in obese mice, revealing a potential metabolic effect beyond appetite suppression. If confirmed in humans, the

Saturday, September 26 – Chipotle, McDonald’s and Shake Shack are among the restaurant chains revamping their menus as more consumers go on weight-loss drugs.

Saturday, September 26 – Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a reported 5-year survival rate of approximately 13.3%, largely because of late diagnosis, rapid progression and resistance

Friday, September 25 – Mylan Pharmaceuticals Inc. has launched a lawsuit in Delaware federal court asking for a finding that its proposed generic version of Novo Nordisk Inc.’s blockbuster weight

Friday, September 25 – FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site

Friday, September 25 – People taking popular GLP-1 medications such as Ozempic, Wegovy and Zepbound may face stigma from those closest to them, according to a new study by a

Friday, September 25 – Children taking GLP-1 medications (such as Victoza, Saxenda, Trulicity, and Ozempic) for weight loss, prediabetes, or type 2 diabetes may face an overlooked risk: nutritional deficiencies.

Thursday, September 24 – Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal suggests that this effect cannot

Thursday, September 24 – (MedPage Today) — The FDA issued a warning letter this month to Empower Pharmacy over its mass production of compounded GLP-1 weight-loss and diabetes drugs, citing

Thursday, September 24 – Woman who used semaglutide and lost vision is among people suing the makers of GLP-1 weight-loss drugs for not being warned about potential vision loss.

Wednesday, September 23 – Viking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more

Wednesday, September 23 – With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.

Wednesday, September 23 – With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented

Wednesday, September 23 – (MedPage Today) — Note that some links may require registration or subscription.
Dozens of Americans sued manufacturers of GLP-1 receptor agonists, claiming the drugmakers failed

Wednesday, September 23 – The mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from

Wednesday, September 23 – Heidi Skolnik, a sports nutritionist, exercise physiologist and bestselling author, joins TODAY to discuss her latest book, “Your GLP-1 Game Plan,” that is filled with guidance

Wednesday, September 22 – About 11% of Americans are taking a GLP-1 medication, up considerably from 3% in 2024, according to a recent Gallup poll.

Tuesday. September 22 – Hundreds of Americans are suing GLP-1 drugmakers Novo Nordisk and Ely Lilly, saying they were not adequately warned of the potential danger of vision loss. In

Tuesday. September 22 – Children prescribed GLP-1 medications for weight loss, prediabetes or type 2 diabetes are at risk for nutritional deficiencies—diagnosed in nearly one in six patients (16.8%) within

Tuesday, September 22 – GLP-1 drugs have revolutionized obesity treatment, but they can lead people to lose muscle mass along with fat. And when patients stop treatment, they often regain

Tuesday, September 22 – A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two

Saturday, September 19 – Research shows that microdosing GLP-1 medications may still lead to weight loss. Tatsiana Volkava · Moment/Getty

Recent research suggests that people may still lose weight while

Saturday, September 19 – (MedPage Today) — Frailty did not appear to prevent adults with cardiovascular disease and overweight or obesity from reaping the benefits of semaglutide (Wegovy), a secondary

Saturday, September 19 – Ozempic and other GLP-1 medications can improve blood sugar, weight, and cardiovascular health, but researchers found little evidence that they also improve mental health, employment, marriage,

Friday, September 18 – Millions of people worldwide—as many as 1 in 8 adults in the U.S.—are taking GLP-1 medications, such as Ozempic, Mounjaro, Wegovy and Zepbound, to treat diabetes

Thursday, September 17 – Retatrutide, an experimental weight loss drug still undergoing clinical trials at Eli Lily, is being marketed online and illegally sold to U.S. clients, a CBS News

An Illinois federal judge is weighing whether the state’s genetic privacy law protects against disclosing information about people who have taken genetic tests, with a DNA testing company accused of

Thursday, September 17 – Elvinix Inc. has announced an exclusive license agreement with Zealand Pharma A/S granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio.

Wednesday, September 16 – (MedPage Today) — An international consensus panel outlined the first clinical framework for implementing general-population screening for islet autoantibodies to catch early-stage type 1 diabetes. (Diabetologia)<br

Tuesday, September 15 – (MedPage Today) — Blockbuster GLP-1 receptor agonists revolutionized obesity management in recent years, driving weight loss of up to 20%.
This weight loss, however, can

Tuesday, September 15 – The one health care policy Republicans agree on, and a look at how rural providers are approaching AI.

Monday, September 14 – A study linked 15 cases of Wernicke encephalopathy to GLP-1 drugs like Ozempic and Mounjaro, raising concerns about vitamin B1 deficiency risks.

AI analysis of 400,000 Reddit posts found that users of drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound reported unexpected symptoms including menstrual changes, chills, hot flashes, and fatigue. Researchers

GLP-1 drugs such as Ozempic, Wegovy, and Zepbound may increase hair-loss risk by 7% in men who are already genetically susceptible to male-pattern baldness. The findings suggest thinning hair may

Sunday, September 13 – Semaglutide helped older healthy mice live longer while improving memory, muscle function, blood sugar control, and several biological signs of aging. Its effects went beyond those

Saturday, July 4 – On June 16, 2026, the US Food and Drug Administration (FDA) issued 25 warning letters to various telehealth companies alleging that their websites contained false or

Tuesday, May 19 – Semaglutide for Weight Loss Without Diabetes: What the Approval Covers, What Programs Skip, and What Results Actually Look Like